TSC-102-A0301 / TSCan Therap - LARVOL DELTA

Novel CD45-targeted TCR-T cell therapies designed to eliminate residual disease and prevent relapse following allogeneic hematopoietic cell transplantation (ASGCT 2026) - P1 | "One such investigational product, TSC-101, targets the HA-2 minor histocompatibility antigen that is present on all blood cells. Conclusion As TSC-102-A01 and TSC-102-A03 TCR-T cells display highly specific and potent in vitro activity with no projected allo- or off-target activity, TScan is advancing these TCR-T cell therapies to clinical development. By expanding our portfolio of TCR-T cell therapies to include products that could treat HLA-A*02:01-, HLA-A*01:01-, or HLA-A*03:01-positive patients, we anticipate that ~70% of the US population undergoing HCT for hematologic malignancies could be eligible for a TCR-T cell therapy designed to prevent relapse."

Residual disease • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Transplantation • HLA-A • PTPRC

TScan Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (TScan Therap Press Release) - "Updates from the PLEXI-T solid tumor and ALLOHA heme Phase 1 clinical trials anticipated by end of year; On-track to file IND application for TSC-102-A0301 (CD45; HLA-A*03:01) to FDA in the second half of the year...Plans to present additional data from the ALLOHA Phase 1 trial by the end of the year, including two-year relapse data on the initial patients."

Commercial • IND • P1 data • Trial status • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Myelodysplastic Syndrome • Solid Tumor

TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) - "Heme Malignancies Program: TScan’s two lead TCR-T therapy candidates, TSC-100 and TSC-101...Opened expansion cohorts at dose level 3 to further characterize safety and evaluate translational and efficacy endpoints. Plans to continue development of TSC-101 only, as TSC-101 enables treatment of ~98% of patients with HLA type A*02:01. Initiate a registration trial for TSC-101, pending further feedback from regulatory authorities, in the second half of 2025. Plans to present additional data from the Phase 1 trial by the end of the year, including two-year relapse data on the initial patients. Plans to file an investigational new drug (IND) application for TSC-102-A0301, a TCR-T targeting CD45 on HLA-A*03:01, in the second half of 2025."

IND • New trial • P1 data • Trial status • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Myelodysplastic Syndrome